What's new? Log in Free sign up

Affimed (AFMD)

Company Profile

Company profile

Ticker

AFMD

Exchange

Website

www.affimed.com

CEO

Dr. Shawn M. Leland Pharm.D., R.Ph.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris • AbbVie • Bausch Health Companies ...

Former names

Affimed Therapeutics B.V.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

AFMD stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

Affimed Reports Positive Clinical Update on AFM24/Atezolizumab

Unaudited consolidated interim statements of comprehensive loss

Notice of effectiveness

Prospectus supplement for primary offering

Shelf registration (foreign)

Current report (foreign)

Current report (foreign)

Unaudited consolidated interim statements of comprehensive loss

Affimed Appoints Shawn M. Leland as Chief Executive Officer

Current report (foreign)

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

683 Capital Management, LLC

683 Capital Management, LLC

Ridgeback Capital Investments L.P.

683 Capital Management, LLC

Ridgeback Capital Investments L.P.

Point72 Asset Management, L.P.

683 Capital Management, LLC

Ridgeback Capital Investments L.P.

Financial summary

Financial statements Chart AFMD financial data

Quarter (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Affimed earnings reports.

Institutional ownership, Q3 2024

AFMD institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	43	49	-12.2%
Opened positions	8	8	–
Closed positions	14	6	+133.3%
Increased positions	6	11	-45.5%
Reduced positions	9	6	+50.0%

13F shares	Current	Prev Q	Change
Total value	10.19 bn	16.13 bn	-36.8%
Total shares	18.02 mm	17.97 mm	+0.3%
Total puts	12.30 k	80.10 k	-84.6%
Total calls	8.70 k	532.51 k	-98.4%
Total put/call ratio	1.4	0.2	+839.9%

Largest owners	Shares	Value	Change
Gilde Healthcare Holding B.V.	8.13 mm	$32.09 mm	0.0%
SGR Sagittarius Holding	4.59 mm	$19.15 mm	0.0%
Integrated Core Strategies	2.26 mm	$13.13 mm	0.0%
683 Capital Management	650.00 k	$2.18 bn	0.0%
NEA Management	442.65 k	$1.49 bn	-0.0%
Point72 Asset Management	342.86 k	$1.15 bn	+4.6%
Millennium Management	340.62 k	$1.14 bn	-8.6%
MS Morgan Stanley	222.42 k	$747.34 mm	-20.5%
Eversept Partners	166.46 k	$559.31 mm	0.0%
Tang Capital Management	148.32 k	$498.34 mm	NEW

Largest transactions	Shares	Bought/sold	Change
Tang Capital Management	148.32 k	+148.32 k	NEW
Marshall Wace	114.54 k	+103.52 k	+939.4%
MS Morgan Stanley	222.42 k	-57.38 k	-20.5%
STT State Street	0.00	-55.09 k	EXIT
Verition Fund Management	91.07 k	-41.02 k	-31.1%
Millennium Management	340.62 k	-32.17 k	-8.6%
Walleye Capital	0.00	-24.11 k	EXIT
Dimensional Fund Advisors	18.12 k	+18.12 k	NEW
Jump Financial	0.00	-17.73 k	EXIT
BLK BlackRock	0.00	-16.28 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Affimed Reports Results for Cancer Therapy in NSCLC Patients

Affimed N.V. (NASDAQ:AFMD) ("Affimed," or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced updated clinical data from the

Wells Fargo Maintains Overweight on Affimed, Lowers Price Target to $15

Wells Fargo analyst Yanan Zhu maintains Affimed (NASDAQ:AFMD) with a Overweight and lowers the price target from $20 to $15.

HC Wainwright & Co. Reiterates Buy on Affimed, Maintains $10 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Affimed (NASDAQ:AFMD) with a Buy and maintains $10 price target.

Affimed Reports Phase 1 Efficacy And Safety Data For AFM28 In Relapsed/Refractory Acute Myeloid Leukemia; AFM28, A Bispecific, Tetravalent Innate Cell Engager Targeting CD123 And CD16A, Achieved A 40% Composite Complete Remission Rate At The Highest Dose Level In Heavily Pretreated R/R AML Patients

Affimed to Review Clinical Data from Lung Cancer Trial on December 17

Press releases

From Benzinga Pro

Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)

In 33 heavily pretreated NSCLC EGFR wild-type (EGFRwt) patients the combination of AFM24 and atezolizumab shows an overall response rate (ORR) of 21% (6 confirmed responses, 1 response awaiting confirmatory scan) and a

Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

AFM28, a bispecific, tetravalent innate cell engager (ICE®) targeting CD123 and CD16A, achieved a 40% composite complete remission rate (CRcR) at the highest dose level (300 mg) in heavily pretreated R/R AML

Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer

MANNHEIM, Germany, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight

Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients

Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.